SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology
Healthcare
$17.95 +4.02%
+$0.31 today
- Market cap
- $3.66B
- Beta
- 2.53
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.17
52W Low $1.39High $9.51
Volume 35.53M
Average 7.79M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$28.27M
FY 2025 · Annual
Net Income
-$26.86M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.6M | 1M | 0 | 0 | 0 |
| Cost of Revenue | 200K | 100K | 0 | 0 | 0 |
| Gross Profit | 7.4M | 900K | 0 | 0 | 0 |
| Gross Margin | 97.4% | 90.0% | — | — | — |
| Research & Development | 21.37M | 30.27M | 24.01M | 19.1M | 16.02M |
| Selling, General & Admin | 11.32M | 12.58M | 13.86M | 12.42M | 12.25M |
| Operating Expenses | 32.69M | 42.85M | 37.87M | 31.51M | 28.27M |
| Depreciation & Amortization | 1.27M | 457K | 37.87M | 31.51M | 0 |
| EBITDA | (18.32M) | (31.49M) | 529K | 632K | (26.86M) |
| EBITDA Margin | -241.1% | -3149.3% | — | — | — |
| Operating Income | (25.29M) | (41.95M) | (37.87M) | (31.51M) | (28.27M) |
| Operating Margin | -332.8% | -4195.0% | — | — | — |
| Interest Income | 6K | 317K | 525K | 632K | 1.41M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.36M | 649K | 529K | 632K | 1.41M |
| Income Before Tax | (20.94M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Pre-Tax Margin | -275.5% | -4130.1% | — | — | — |
| Income Tax Expense | (237K) | 0 | 0 | 0 | 0 |
| Net Income | (20.7M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Net Margin | -272.4% | -4130.1% | — | — | — |
| EPS (Basic) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| EPS (Diluted) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| 15.48M | 19.4M | 27.78M | 61.2M | 109.05M | |
| 15.48M | 19.4M | 27.78M | 61.2M | 109.05M |
SLS Earnings Waterfall · TTM
NASDAQ:SLS · Revenue to Net Income
Key Ratios
EPS$-0.20
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-44.0
P/S Ratio0.0
Analysis
$0 of revenue converted into -$35.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.20, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 10-Q | Quarterly report | Aug 11, 2026 |
How much revenue does SLS generate?
SELLAS Life Sciences Group, Inc. (SLS) reported $0.00 of revenue in fiscal 2025.
Is SLS profitable?
SELLAS Life Sciences Group, Inc. (SLS) reported -$26.86M of net income.
Continue the stock analysis
Jump to another research area for this company.